Agenus begins phase 3 trial for colorectal cancer immunotherapy

April 1, 2026 7:30 AM

Agenus Inc. (NASDAQ: AGEN) announced the first patient enrollment in its global phase 3 BATTMAN trial, evaluating the combination of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found